^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    G1-S-specific cyclin-D1 inhibitor

    Related drugs:
    Apply
    Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 (NCT04874194)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    12/17/2021
    Primary completion :
    08/01/2024
    Completion :
    08/01/2024
    RUNX1
    |
    RUNX1 mutation
    |
    Venclexta (venetoclax) • Synribo (omacetaxine mepesuccinate)
    Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. (NCT06328179)
    Phase N/A
    Huai'an First People's Hospital
    Recruiting
    Last update posted :
    03/25/2024
    Initiation :
    05/24/2022
    Primary completion :
    12/30/2027
    Completion :
    12/30/2027
    BCL2
    |
    Venclexta (venetoclax) • cytarabine • etoposide IV • Synribo (omacetaxine mepesuccinate)
    Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML (NCT00462943)
    Phase 2
    Teva Branded Pharmaceutical Products R&D, Inc.
    Completed
    Last update posted :
    12/28/2021
    Initiation :
    03/07/2007
    Primary completion :
    08/04/2009
    Completion :
    06/27/2013
    ABL1 • BCR
    |
    Synribo (omacetaxine mepesuccinate)
    Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation (NCT00375219)
    Phase 2
    Teva Branded Pharmaceutical Products R&D, Inc.
    Completed
    Last update posted :
    11/15/2021
    Initiation :
    09/20/2006
    Primary completion :
    03/23/2010
    Completion :
    06/28/2013
    ABL1 • BCR
    |
    Synribo (omacetaxine mepesuccinate)
    Azacitidine and Homoharringtonine in JMML (NCT04505995)
    Phase N/A
    Fourth Military Medical University
    Recruiting
    Last update posted :
    08/10/2020
    Initiation :
    01/01/2020
    Primary completion :
    01/01/2023
    Completion :
    01/01/2025
    KRAS • NRAS • PTPN11
    |
    KRAS mutation • NRAS mutation • PTPN11 mutation
    |
    azacitidine • Synribo (omacetaxine mepesuccinate)